FilingSEC EDGAR6-K
Adagene Receives NMPA Approval for ADG138 Phase 1 Clinical Trial in China
· SEC accepted
StagePhase 1 Preparation
Filing content
Adagene has received IND approval from China's NMPA for ADG138, a HER2xCD3 bispecific T-cell engager, and expects to initiate a Phase 1 study for advanced solid tumors in Q4 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…